• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Amin I. Kassis, PhD

Professor, Department of Radiology, Harvard Medical School

Director, Radiation Biology and Experimental Radionuclide Therapy Section, Brigham And Women's Hospital

Contact Info

Amin Kassis
Harvard Medical School
200 Longwood Avenue
Boston, MA, 02115
Mailstop: Armenise Bldg, Rm 137
Phone: 617-432-7777
Fax: 617-432-2419
amin_kassis@hms.harvard.edu

Assistant

Not Available.

DF/HCC Program Affiliation

Cancer Risk and Disparities
Cancer Imaging

Lab Website

Kassis-LabKassis Lab

Research Abstract

The major objective of the research in my laboratories is the development of radionuclide carrier systems suitable for the specific delivery of diagnostic and therapeutic radioactive moieties to cancerous cells. The goal is to maximize the effectiveness of radiotherapeutic agents while minimizing their toxicity to normal tissues. We have synthesized proprietary radiolabeled thymidine analogs and documented their radiodiagnostic and radiotherapeutic potential following locoregional administration in tumor-bearing animals. These results represent promising observations on a novel approach to cancer treatment with unsealed radioactive sources. Pharmacokinetics studies in cancer patients have shown the approach to be equally effective. More recently, we have been developing a proprietary technology (Enzyme-Mediated Cancer Imaging and Therapy) that aim to irreversibly entrap and concentrate diagnostic and therapeutic radionuclides within solid tumors.

A second objective is to define and establish the biophysical relationship between the intracellular localization of low-energy-electron-emitting radionuclides and the biologic consequences of the resulting microdistribution of energy. This work is leading to more accurate delineation of the risks associated with the use of radiopharmaceuticals in the field of nuclear medicine.

Most recently, we have also been developing novel blood assays for the noninvasive blood-based detection of occults tumors (primary and metastatic). Using these assays, we have been able to detect cancer-specific signatures (genomic and proteomic) in mice bearing melanoma and prostate, lung, and colon cancer as well as in patients with head and neck cancer, thyroid cancer, and ovarian cancer.

Publications

View All Publications